首页> 外文期刊>World Allergy Organization Journal >Safety and value of skin test to sex hormones and sex hormone sensitivity desensitization in women with premenstrual syndrome
【24h】

Safety and value of skin test to sex hormones and sex hormone sensitivity desensitization in women with premenstrual syndrome

机译:皮肤检测对患有生长综合征的女性性激素和性激素敏感性脱敏的安全性和价值

获取原文
           

摘要

Hypersensitivity to one's own sex hormones is not a new concept but it is an underappreciated one. Such a phenomenon may explain a large proportion of symptoms related to the menstrual cycle (such as premenstrual syndrome, PMS), cyclic pain syndromes or unexplained infertility. In this study we propose a novel diagnostic tool of hormonal skin testing which reveals sex hormones sensitivity with high clinical correlation, and a subsequent successful desensitization technique. A group of 35 women with confirmed diagnosis of PMS were enrolled in the study in which they underwent a hormonal skin diagnostic skin testing procedure by intradermal injections of Progesterone (P), Estradiol (E2), Estrone (E1) and Estriol (E3). Skin reaction was monitored, and according to the reaction the patients were treated by serial desensitization by similar serial injections or placebo solvent. Response to treatment was monitored by assessing the change in the severity of PMS related symptoms. We show a positive correlation between PMS severity and skin sensitivity to sex hormones. Subsequent desensitization procedure led to a significant improvement in the severity of PMS related symptoms. The testing and desensitization procedure is safe, sensitive and bares a high therapeutic potential in approach to resistant hormonal cycle related syndromes. NCT00873262: Evaluation of Safety/Efficacy of Diagnostic Skin Test Panel and Desensitization Hormone Kit for Treatment of Premenstrual Syndrome (PMS) 2009.
机译:对一个人自己的性激素的过敏不是一个新的概念,但它是一个被批评的人。这种现象可以解释与月经周期(例如经前综合征,PMS),循环疼痛综合征或无法解释的不孕症相关的大部分症状。在这项研究中,我们提出了一种新的荷尔蒙皮肤检测诊断工具,揭示了性激素敏感性,具有高临床相关性,以及随后的成功脱敏技术。通过皮蛋白质(P),雌二醇(E2),雌激素(E2),雌激素(E3)和雌激素(E3),纳入其中一项患有PMS确诊的PMS诊断的35名患有PMS诊断的妇女。监测皮肤反应,并根据反应,通过相似的连续注射或安慰剂溶剂通过串联脱敏处理患者。通过评估PMS相关症状的严重程度的变化来监测对治疗的反应。我们展示了PMS严重程度与皮肤敏感性与性激素之间的正相关性。随后的脱敏程序导致PMS相关症状的严重程度的显着改善。测试和脱敏程序是安全的,敏感的,并且在抗血管循环相关综合征的方法中具有高治疗潜力。 NCT00873262:诊断皮肤试验板的安全/疗效评估和脱敏激素试剂盒治疗前瞻性综合征(PMS)2009。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号